FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma
Abstract
ABSTRACT Background Fibrinogen‐like protein 1 (FGL1) is involved in tumor progression and immune regulation, but its role in laryngeal squamous cell carcinoma (LSCC) is unclear. Methods Plasma FGL1 levels were measured in 120 LSCC patients and 50 controls using ELISA. Tissue expression was analyzed via TCGA‐HNSC. Functional assays evaluated proliferation, migration, invasion, apoptosis, and cisplatin sensitivity. Prognostic value was assessed using survival and regression analyses. Results FGL1 was significantly elevated in LSCC plasma and tumor tissues. Functional studies showed that FGL1 promotes proliferation, migration, invasion, and EMT while inhibiting apoptosis and enhancing cisplatin resistance. Mechanistically, FGL1 knockdown increased Cleaved Caspase‐3 and decreased Bcl‐2 expression. High FGL1 levels were associated with poorer overall survival and independently predicted prognosis. Conclusion FGL1 promotes LSCC progression and chemoresistance, highlighting its potential as a circulating biomarker and therapeutic target.